0000313143-18-000050.txt : 20180807 0000313143-18-000050.hdr.sgml : 20180807 20180807060801 ACCESSION NUMBER: 0000313143-18-000050 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 3 CONFORMED PERIOD OF REPORT: 20180807 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20180807 DATE AS OF CHANGE: 20180807 FILER: COMPANY DATA: COMPANY CONFORMED NAME: HAEMONETICS CORP CENTRAL INDEX KEY: 0000313143 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 042882273 STATE OF INCORPORATION: MA FISCAL YEAR END: 0331 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-14041 FILM NUMBER: 18996197 BUSINESS ADDRESS: STREET 1: 400 WOOD RD CITY: BRAINTREE STATE: MA ZIP: 02184 BUSINESS PHONE: 7818487100 MAIL ADDRESS: STREET 1: 400 WOOD ROAD CITY: BRAINTREE STATE: MA ZIP: 02184 8-K 1 q1jun2019form8-k.htm 8-K Document


UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
FORM 8-K
 
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934
 Date of Report (Date of earliest event reported)   August 7, 2018
 HAEMONETICS CORPORATION
(Exact name of registrant as specified in its charter)
 
Massachusetts
 
001-14041
 
04-2882273
(State or other jurisdiction
of incorporation)
 
(Commission
File Number)
 
(I.R.S. Employer
Identification No.)
 
400 Wood Road
 
02184
(Address of principal executive offices)
 
Zip code
 
Registrant's telephone number, including area code  781-848-7100
 
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
 
 
o
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
 
o
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
 
o
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
 
o
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
 
 
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Emerging growth company
o
 
 
 
 
 
 
 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the
 
 
Exchange Act.
o







Item 2.02               RESULTS OF OPERATIONS AND FINANCIAL CONDITION
 
On August 7, 2018, Haemonetics Corporation issued a press release announcing financial results for the first quarter ended June 30, 2018. A copy of the release is furnished with this report as exhibit 99.1.
 
The foregoing information, including the exhibit attached hereto, shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, regardless of any general incorporation language in such filing.


Item 9.01               FINANCIAL STATEMENTS AND EXHIBITS

99.1: Press Release of Haemonetics Corporation dated August 7, 2018 announcing financial results for the first quarter ended June 30, 2018.

 
SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
 
 
 
 
 
HAEMONETICS CORPORATION
 
 
 
 
 
 
 
 
Date: August 7, 2018
By:
/s/ Christopher Simon
 
 
Christopher Simon, President, Director and
 
 
Chief Executive Officer




EX-99.1 2 ex991-q1jun2019earningsrel.htm EXHIBIT 99.1 Exhibit
image0a08.jpg

 
 
 
Exhibit 99.1
 
 
 
 
Earnings Release FY19 Q1
Investor Contact
Media Contact
 
 
Gerry Gould, VP-Investor Relations
Carla Burigatto, VP-Communications
 
 
(781) 356-9402
(781) 348-7263
 
 
gerry.gould@haemonetics.com
carla.burigatto@haemonetics.com
 
 
 
 
Haemonetics Reports 1st Quarter Fiscal 2019 Results; Affirms Fiscal Year 2019 Revenue, Adjusted EPS and Cash Flow Guidance

Braintree, MA, August 7, 2018 - Haemonetics Corporation (NYSE: HAE) reported financial results for its first fiscal 2019 quarter, which ended June 30, 2018:

 
 
1st Quarter 2019
Revenue, increase
 
$229 million, +9%
Revenue increase, constant currency
 
+7%
Net loss per share
 
($0.05)
Adjusted net income per diluted share
 
$0.59
Cash flow from operating activities
 
$23 million
Free cash flow before restructuring & turnaround
 
$6 million

Chris Simon, Haemonetics’ CEO, stated: “Our first quarter revenue and adjusted earnings provide evidence that our turnaround plans are working and increase our confidence in achieving profitable accelerated growth. The investments we are making, coupled with strong market demand, drove overall revenue growth and operating leverage.”

GAAP RESULTS

Revenue of $229.3 million was up $18.4 million or 8.7% compared to the first quarter of fiscal 2018. Business unit revenue and revenue growth rates versus the prior year first quarter were as follows ($ million):
 
 
Plasma
$116.9
+ 15.2%

Hospital
$48.0
+ 9.3%

Blood Center
$64.5
(1.7
)%

Gross margin was 36.3% in the first quarter of fiscal 2019, down 720 basis points compared to the prior year first quarter, as $25.1 million of asset impairment charges and accelerated depreciation were included in the first quarter of fiscal 2019.

Operating expenses were $78.0 million in the first quarter of fiscal 2019, up $2.9 million or 3.9% versus the prior year first quarter. Additionally $3.4 million and $2.4 million of restructuring and turnaround costs were included in operating expenses in the first quarters of fiscal 2019 and 2018, respectively.

1

image0a08.jpg


Including $25.1 million of asset impairment charges and accelerated depreciation, operating income in the first quarter of fiscal 2019 was $5.3 million, down $11.3 million compared with the first quarter of the prior fiscal year. The Company reported a first quarter 2019 net loss of ($2.8) million or ($0.05) per share, compared with net income of $20.1 million or $0.38 per diluted share in the prior year’s first quarter.

ADJUSTED RESULTS

On a constant currency basis, revenue for the first quarter of fiscal 2019 was up 7.2% compared to the prior year first quarter. Business unit revenue growth rates, which exclude the impact of currency, compared with the prior fiscal year first quarter, were as follows:

 
 
Plasma
+ 14.0%

Hospital
+ 6.3%

Blood Center
(3.1
)%

Plasma revenue growth in North America was 17.1% in the first quarter of fiscal 2019 and included 15.3% growth in disposables coupled with strength in liquid solutions and software revenues. Subsequent to the first quarter of fiscal 2019, the Company entered into long-term commercial contracts and began rollout with several Plasma customers for the delivery of NexSys PCS™ devices and NexLynk DMS™ donor management software. Within Hospital, revenue growth in the Hemostasis Management product line was 20.6% in the first quarter of fiscal 2019.

In the first quarter of fiscal 2019, adjusted gross margin was 47.2%, up 370 basis points compared with the same quarter of the prior year, due to Complexity Reduction Initiative savings, favorable revenue volume and product mix, and the inclusion in the prior year first quarter of costs related to liquid solutions production delays. Additionally, 140 basis points of improvement were attributable to favorable foreign currency.

Adjusted operating expenses were $67.6 million, up $1.5 million or 2.2%, as the Company continued to make planned investments to accelerate revenue growth. Adjusted operating income was $40.7 million, up $15.1 million, or 59.2%, while adjusted operating margin was 17.8%, up 570 basis points as compared with the first quarter of fiscal 2018. The adjusted tax rate of 18.0% in the first quarter of fiscal 2019 compares with an adjusted tax rate of 27.9% in the prior year first quarter, reflecting benefits from recent U.S. tax reform and continuation of a favorable geographic income shift.

First quarter adjusted net income was $31.8 million, up $14.3 million, and adjusted earnings per share was $0.59 versus $0.33 in the first quarter of fiscal 2018.






2

image0a08.jpg


BALANCE SHEET AND CASH FLOW

Cash on hand at the end of the first quarter of fiscal 2019 was $192.1 million, an increase of $11.9 million in the quarter. The Company realized net cash proceeds of $94.1 million upon refinancing its debt and $4.6 million from employee stock programs during the first quarter of fiscal 2019. Cash utilized included $80.0 million for repurchasing shares and $10.2 million for restructuring and turnaround initiatives net of tax benefits.

First quarter fiscal 2019 free cash flow was ($4.1) million, including net restructuring and turnaround funding, and $6.0 million before such funding.

SHARE REPURCHASE PROGRAM

As part of its previously announced $260 million share repurchase program, the Company repurchased 0.85 million of its common shares for $80 million via an accelerated share repurchase (“ASR”) agreement with Citibank N.A that was completed on August 1, 2018. Together with a previous ASR program completed in May, 2018 the Company has repurchased 2.2 million shares and disbursed $180 million.

ASSET IMPAIRMENTS, RESTRUCTURING AND TURNAROUND EXPENSES, DEAL AMORTIZATION AND GAIN ON DIVESTITURE

The Company incurred charges totaling $25.1 million in the first quarter of fiscal 2019, comprised of $21.2 million of asset impairments and $3.9 million of accelerated depreciation. The impairments were mostly related to the write-off of a non-strategic production line in the Blood Center business. The accelerated depreciation was related to PCS® 2 devices in the Plasma business and will continue throughout the NexSys PCS rollout.

The Company incurred $3.3 million of restructuring and turnaround expenses and $0.7 million of legal charges in the first quarter of fiscal 2019 and $2.5 million of restructuring and turnaround expenses in the first quarter of fiscal 2018.
 
These impairments, accelerated depreciation, expenses and charges were excluded from the computation of adjusted earnings, as were deal amortization expenses of $6.3 million and $6.5 million in the first quarters of fiscal 2019 and 2018, respectively. Also excluded from first quarter fiscal 2018 adjusted earnings was a gain of $8.0 million realized upon divestiture of the Company’s SEBRA line of benchtop and hand held sealers.











3

image0a08.jpg


GUIDANCE

The Company affirmed previous fiscal 2019 guidance for constant currency revenue growth, adjusted earnings and cash flows, and lowered its guidance for operating margin (GAAP) and earnings per diluted share (GAAP) to reflect the first quarter impact of asset impairments and accelerated depreciation summarized as follows:

 
 
FY 2019
Plasma revenue including 10-14% growth in North America
 
7-10%
Hospital revenue including double-digit percentage growth in Hemostasis Mgmt.
 
5-8%
Blood Center revenue
 
(3-6%)
Total revenue
 
3-5%
Operating Margin (GAAP)
 
7-9%
Adjusted Operating Margin
 
16-18%
Earnings per Diluted Share (GAAP)
 
$0.70 - $0.90
Adjusted Earnings per Diluted Share
 
$2.00 - $2.30
Cash Flow from Operating Activities (GAAP)
 
$150 - $175 million
Free Cash Flow, Before Restructuring & Turnaround
 
$25 - $50 million

WEBCAST CONFERENCE CALL AND RESULTS ANALYSIS

The Company will host a conference call with investors and analysts to discuss first quarter fiscal 2019 results on Tuesday, August 7, 2018 at 8:00am Eastern Time. Interested parties may participate by telephone by dialing (877) 848-8880 from within the U.S. or Canada or (716) 335-9513 from international locations, using the access code 6164607. Alternatively, a live webcast of the call can be accessed on Haemonetics’ investor relations website at the following direct link: https://edge.media-server.com/m6/p/bcyyy75d.

The Company is posting this press release to its Investor Relations website, in addition to results analyses that will be referenced on the webcast. These analyses can be accessed by the following direct link:
http://phx.corporate-ir.net/External.File?item=UGFyZW50SUQ9NDA5MTk2fENoaWxkSUQ9LTF8VHlwZT0z&t=1&cb=636682931304087427.

ABOUT HAEMONETICS

Haemonetics (NYSE: HAE) is a global healthcare company dedicated to providing a suite of innovative hematology products and solutions for customers, to help them improve patient care and reduce the cost of healthcare. Our technology addresses important medical markets: blood and plasma component collection, the surgical suite, and hospital transfusion services. To learn more about Haemonetics, visit www.haemonetics.com.



4

image0a08.jpg


FORWARD LOOKING STATEMENTS

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Forward-looking statements in this press release may include, without limitation, statements regarding (i) plans and objectives of management for operations of the Company, including plans or objectives related to the development and commercialization of, and regulatory approvals related to, the Company’s products, (ii) estimates or projections of financial results, financial condition, capital expenditures, capital structure or other financial items, (iii) the Company's future financial performance and (iv) the assumptions underlying or relating to any statement described in points (i), (ii) or (iii) above. Such forward-looking statements are not meant to predict or guarantee actual results, performance, events or circumstances and may not be realized because they are based upon the Company's current projections, plans, objectives, beliefs, expectations, estimates and assumptions and are subject to a number of risks and uncertainties and other influences. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. Factors that may influence or contribute to the inaccuracy of the forward-looking statements or cause actual results to differ materially from expected or desired results may include, without limitation, technological advances in the medical field and standards for transfusion medicine and our ability to successfully offer products that incorporate such advances and standards, product quality, market acceptance, regulatory uncertainties, including in the receipt or timing of regulatory approvals, the effect of economic and political conditions, the impact of competitive products and pricing, blood product reimbursement policies and practices, and the effect of industry consolidation as seen in the plasma market.  These and other factors are identified and described in more detail in the Company's filings with the SEC. The Company does not undertake to update these forward-looking statements.

MANAGEMENT’S USE OF NON-GAAP MEASURES

Management uses non-GAAP measures to monitor the financial performance of the business, make informed business decisions, establish budgets, and forecast future results.

In this release, supplemental non-GAAP measures have been provided to assist investors in evaluating the performance of the Company’s core operations. When used in this release, constant currency measures the change in revenue using a constant currency conversion rate. Adjusted operating income, net income and earnings per share exclude restructuring and turnaround and deal amortization expenses, asset impairments, accelerated depreciation and legal charges. Adjusted net income and earnings per share also exclude gains and losses on asset dispositions. Free cash flow before restructuring and turnaround is defined as cash provided by operating activities less capital expenditures, net of the proceeds from the sale of property, plant and equipment.

Reconciliations of these measures to their most comparable GAAP measure are included at the end of the financial sections of this press release as well as on the Company’s website at www.haemonetics.com.


5

image0a08.jpg

 
Haemonetics Corporation Financial Summary
Condensed Consolidated Statements of (Loss) Income for the First Quarter of FY19 and FY18
(Data in thousands, except per share data)
 
 
 
 
 
 
 
 
 
6/30/2018
 
7/1/2017
 
% Inc/(Dec)
 
 
 
 
vs Prior Year
 
 
(unaudited)
 
 
Net revenues
$
229,347

 
$
210,951

 
8.7%
Gross profit
83,244

 
91,665

 
(9.2)%
 
 
 
 
 
 
 
 
R&D
9,406

 
8,193

 
14.8%
 
S,G&A
68,545

 
66,861

 
2.5%
Operating expenses
77,951

 
75,054

 
3.9%
 
 
 
 
 
 
 
Operating income
5,293

 
16,611

 
(68.1)%
 
 
 
 
 
 
 
Gain on divestiture

 
8,000

 
(100.0)%
Interest and other expense, net
(1,978
)
 
(1,359
)
 
45.5%
Income before taxes
3,315

 
23,252

 
(85.7)%
 
 
 
 
 
 
 
Tax expense
6,134

 
3,115

 
96.9%
 
 
 
 
 
 
 
Net (loss) income
$
(2,819
)
 
$
20,137

 
n/m
 
 
 
 
 
 
 
 
 
 
 
 
 
Net (loss) income per common share assuming dilution
$
(0.05
)
 
$
0.38

 
n/m
 
 
 
 
 
 
 
Weighted average number of shares:
 
 
 
 
 
 
Basic
52,119

 
52,443

 
 
 
Diluted
52,119

 
52,811

 
 
 
 
 
 
 
 
 
Profit Margins:
 
 
 
 
Inc/(Dec) vs prior year profit margin %
Gross profit
36.3
 %
 
43.5
%
 
(7.2)%
R&D
4.1
 %
 
3.9
%
 
0.2%
S,G&A
29.9
 %
 
31.7
%
 
(1.8)%
Operating income
2.3
 %
 
7.9
%
 
(5.6)%
Income before taxes
1.4
 %
 
11.0
%
 
(9.6)%
Net (loss) income
(1.2
)%
 
9.5
%
 
(10.7)%




6

image0a08.jpg

Revenue Analysis for the First Quarter of FY19 and FY18
(Data in thousands)
 
 
 
 
 
 
 
 
 
Three Months Ended
 
 
 
 
 
 
 
 
6/30/2018
 
7/1/2017
 
Reported growth
 
Currency impact
 
Constant currency growth (1)
 
 
(unaudited)
 
 
 
 
 
 
Revenues by geography
 
 
 
 
 
 
 
 
 
 
United States
$
142,140

 
$
131,052

 
8.5
 %
 
%
 
8.5
 %
 
International
87,207

 
79,899

 
9.1
 %
 
4.0
%
 
5.1
 %
Net revenues
$
229,347

 
$
210,951

 
8.7
 %
 
1.5
%
 
7.2
 %
 
 
 
 
 
 
 
 
 
 
 
Revenues by business unit
 
 
 
 
 
 
 
 
 
 
Plasma
$
116,903

 
$
101,507

 
15.2
 %
 
1.2
%
 
14.0
 %
 
Blood Center
64,483

 
65,565

 
(1.7
)%
 
1.4
%
 
(3.1
)%
 
Hospital(2)
47,961

 
43,879

 
9.3
 %
 
3.0
%
 
6.3
 %
Net revenues
$
229,347

 
$
210,951

 
8.7
 %
 
1.5
%
 
7.2
 %
(1) Constant currency growth, a non-GAAP financial measure, measures the change in sales between the current and prior year period using a constant currency. See description of non-GAAP financial measures contained in this release.

(2) Hospital revenue includes both Cell Processing and Hemostasis Management revenue. Hemostasis Management revenue was $21.8 million and $17.5 million for the three months ended June 30, 2018 and July 1, 2017, respectively. Hemostasis Management revenue increased 24.0% in the first quarter of fiscal 2019 as compared with the same period of fiscal 2018. Without the effect of foreign exchange, Hemostasis Management revenue increased 20.6% in the first quarter of fiscal 2019 as compared with the same period of fiscal 2018.





7

image0a08.jpg

Condensed Consolidated Balance Sheets
(Data in thousands)
 
 
 
 
 
 
 
As of
 
 
 
6/30/2018
 
3/31/2018
 
 
 
(unaudited)
 
 
Assets
 
 
 
Cash and cash equivalents
$
192,106

 
$
180,169

Accounts receivable, net
151,336

 
151,226

Inventories, net
175,329

 
160,799

Other current assets
32,246

 
28,983

 
 
Total current assets
551,017

 
521,177

Property, plant & equipment, net
315,873

 
332,156

Intangible assets, net
148,730

 
156,589

Goodwill
210,903

 
211,395

Other assets
14,645

 
16,022

 
Total assets
$
1,241,168

 
$
1,237,339

 
 
 
 
 
 
Liabilities & Stockholders' Equity
 
 
 
Short-term debt & current maturities
$
17,043

 
$
194,259

Other current liabilities
176,952

 
190,444

 
 
Total current liabilities
193,995

 
384,703

Long-term debt
330,838

 
59,423

Other long-term liabilities
42,276

 
40,784

Stockholders' equity
674,059

 
752,429

 
Total liabilities & stockholders' equity
$
1,241,168

 
$
1,237,339



8

image0a08.jpg

Condensed Consolidated Statements of Cash Flows
(Data in thousands)
 
 
 
Three Months Ended
 
6/30/2018
 
7/1/2017
 
(unaudited)
Cash Flows from Operating Activities:
 
 
 
Net (loss) income
$
(2,819
)
 
$
20,137

Adjustments to reconcile net (loss) income to net cash provided by operating activities:
 
 
 
Depreciation and amortization
26,415

 
21,789

Gain on divestiture

 
(8,000
)
Stock-based compensation expense
3,379

 
1,343

Impairment of assets
21,170

 

Provision for losses on accounts receivable and inventory
(352
)
 
928

Change in other non-cash operating activities
19

 
658

Change in accounts receivable, net
(1,577
)
 
2,203

Change in inventories, net
(15,058
)
 
1,417

Change in other working capital
(8,055
)
 
(2,050
)
Net cash provided by operating activities
23,122

 
38,425

Cash Flows from Investing Activities:
 
 
 
Capital expenditures
(27,514
)
 
(13,721
)
Proceeds from divestiture

 
9,000

Proceeds from sale of property, plant and equipment
250

 
981

Net cash used in investing activities
(27,264
)
 
(3,740
)
Cash Flows from Financing Activities:
 
 
 
Borrowings, net of repayments
94,052

 
(11,601
)
Share repurchases
(80,000
)
 

Proceeds from employee stock programs
4,611

 
8,052

Net cash provided by (used in) financing activities
18,663

 
(3,549
)
Effect of exchange rates on cash and cash equivalents
(2,584
)
 
1,039

Net Change in Cash and Cash Equivalents
11,937

 
32,175

Cash and Cash Equivalents at Beginning of the Period
180,169

 
139,564

Cash and Cash Equivalents at End of Period
$
192,106

 
$
171,739

 
 
 
 
Free Cash Flow Reconciliation:
 
 
 
Cash provided by operating activities
$
23,122

 
$
38,425

Capital expenditures, net of proceeds from sale of property, plant and equipment
(27,264
)
 
(12,740
)
Free cash flow after restructuring and turnaround costs
(4,142
)
 
25,685

Restructuring and turnaround costs
12,783

 
4,788

Tax benefit on restructuring and turnaround costs
(2,630
)
 
(1,497
)
Free cash flow before restructuring and turnaround costs
$
6,011

 
$
28,976



9

image0a08.jpg

Haemonetics Corporation Financial Summary
Reconciliation of Non-GAAP Measures

Haemonetics has presented supplemental non-GAAP financial measures as part of this earnings release. A reconciliation is provided that reconciles each non-GAAP financial measure with the most comparable GAAP measure. The presentation of non-GAAP financial measures should not be considered in isolation from, or as a substitute for, the most directly comparable GAAP measures. There are material limitations to the usefulness of non-GAAP measures on a standalone basis, including the lack of comparability to the GAAP financial results of other companies.
These measures are used by management to monitor the financial performance of the business, make informed business decisions, establish budgets and forecast future results. Performance targets for management are established based upon these non-GAAP measures. In the reconciliations below, we have removed restructuring, turnaround and other costs from our GAAP expenses. Our restructuring and turnaround costs for the periods reported are principally related to employee severance and retention, program management, implementation of outsourcing initiatives, accelerated depreciation and other costs associated with the fiscal 2018 Complexity Reduction Initiative launched on November 1, 2017.
In addition to restructuring and turnaround costs, we are reporting non-GAAP earnings before deal amortization, asset impairments, accelerated depreciation, legal charges, the impact of tax reform and gain on divestiture.
We believe this information is useful to investors because it allows for an evaluation of the Company with a focus on the performance of our core operations.

10

image0a08.jpg

Reconciliation of Adjusted Measures for the First Quarter of FY19 and FY18
(Data in thousands except per share data)
 
Three Months Ended
 
6/30/2018
 
7/1/2017
 
(unaudited)
GAAP gross profit
$
83,244

 
$
91,665

Impairment of assets
21,170

 

Accelerated depreciation
3,939

 

Restructuring and turnaround costs
(34
)
 
55

Adjusted gross profit
$
108,319

 
$
91,720

 
 
 
 
GAAP operating expenses
$
77,951

 
$
75,054

Restructuring and turnaround costs
(3,383
)
 
(2,428
)
Deal amortization
(6,300
)
 
(6,491
)
Legal charges (1)
(675
)
 

Adjusted operating expenses
$
67,593

 
$
66,135

 
 
 
 
GAAP operating income
$
5,293

 
$
16,611

Impairment of assets
21,170

 

Accelerated depreciation
3,939

 

Restructuring and turnaround costs
3,349

 
2,483

Deal amortization
6,300

 
6,491

Legal charges (1)
675

 

Adjusted operating income
$
40,726

 
$
25,585

 
 
 
 
GAAP net (loss) income
(2,819
)
 
20,137

Impairment of assets
21,170

 

Accelerated depreciation
3,939

 

Restructuring and turnaround costs
3,349

 
2,483

Deal amortization
6,300

 
6,491

Legal charges (1)
675

 

Gain on divestiture

 
(8,000
)
Tax impact associated with adjustments
(826
)
 
(3,639
)
Adjusted net income
$
31,788

 
$
17,472

 
 
 
 
GAAP net (loss) income per common share
$
(0.05
)
 
$
0.38

Adjusted items after tax per common share assuming dilution
$
0.64

 
$
(0.05
)
Adjusted net income per common share assuming dilution
$
0.59

 
$
0.33

(1) Reflects amounts accrued for resolution of customer damages assessments associated with the fiscal 2018 voluntary acrodose recall.




11
GRAPHIC 3 image0a08.jpg begin 644 image0a08.jpg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end